Highest-materiality recent filing
FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7
Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.
Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.
Vera Therapeutics prices public offering of 6.14M shares at $42.50, raising ~$260.9M
Entered underwriting agreement Dec 9 to sell 6,138,108 shares of common stock at $42.50/share.
Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025
Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.
Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw
Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.
Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction
Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.
Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025
Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.
Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done
Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
Vera Therapeutics launches $300M public offering of 7.1M shares at $42.00
7,142,858 shares offered at $42.00/share; gross proceeds ~$300M before discounts and expenses.
Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M
Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies
ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.
Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.
Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track
Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.
On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024
On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.
Max materiality 0.95 · Median 0.70 · Most common event other_material